Crinetics Pharmaceuticals, Inc. (CRNX) — SEC Filings
Crinetics Pharmaceuticals, Inc. (CRNX) — 50 SEC filings. Latest: DEFA14A (Apr 29, 2026). Includes 24 8-K, 10 SC 13G/A, 6 10-Q.
View Crinetics Pharmaceuticals, Inc. on SEC EDGAR
Overview
Crinetics Pharmaceuticals, Inc. (CRNX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Crinetics Pharmaceuticals, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $342.5 million, up from $217.8 million in the same period of 2024. This 57.2% increase was primarily driven by a substantial rise in operating expenses, with research an
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 47 neutral, 1 mixed. The dominant filing sentiment for Crinetics Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Crinetics Pharmaceuticals, Inc. (CRNX) has filed 2 DEFA14A, 24 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13G, 10 SC 13G/A with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of CRNX's 31 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1.5M |
| Net Income | -$342.5M |
| EPS | -$1.38 |
| Debt-to-Equity | 0.12 |
| Cash Position | $1.09B |
| Operating Margin | -25000.0% |
| Total Assets | $1.20B |
| Total Debt | $0.12B |
Key Executives
- Dana Pizzuti
- Matthew Fust
- John F. Milligan
- R. Paul Stuppy
- Dr. Michael R. Levitt
- Dr. David M. Recker
- Dr. David J. E. Wood
- James Hassard
- PEO
- Non-PEO
- Dr. David A. R. Gray
Industry Context
Crinetics operates in the highly competitive biopharmaceutical sector, focusing on developing treatments for rare endocrine diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.
Top Tags
financials (5) · sec-filing (4) · 10-Q (4) · pharmaceuticals (4) · disclosure (3) · regulatory-filing (3) · 8-K (3) · executive-compensation (3) · board-of-directors (3) · Crinetics Pharmaceuticals (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $342.5M | for nine months ended Sep 30, 2025, up 57.2% from $217.8M in 2024 |
| Research and Development Expenses | $247.0M | for nine months ended Sep 30, 2025, up 42.3% from $173.6M in 2024 |
| Selling, General and Administrative Expenses | $137.6M | for nine months ended Sep 30, 2025, up 92.2% from $71.6M in 2024 |
| Revenue | $1.5M | for nine months ended Sep 30, 2025, up from $1.0M in 2024 |
| Accumulated Deficit | $1.3B | as of September 30, 2025 |
| Cash, Cash Equivalents and Investment Securities | $1.1B | as of September 30, 2025, down from $1.35B at Dec 31, 2024 |
| Net Cash Used in Operating Activities | $285.0M | for nine months ended Sep 30, 2025 |
| Net Loss Per Share | $1.38 | for three months ended Sep 30, 2025, up from $0.96 in 2024 |
| Research and Development Expense | $61.5M | Increased from $48.9M in Q2 2024, indicating significant investment in pipeline. |
| General and Administrative Expense | $12.9M | Increased from $10.1M in Q2 2024, supporting growing operations. |
| Cash and Cash Equivalents | $352.0M | Decreased from $378.0M at Dec 31, 2024, showing a burn rate of $26.0M over six months. |
| Revenue Growth | 0% | No revenue generated in either Q2 2025 or Q2 2024, typical for a pre-commercial biotech. |
| Reporting Period | Q1 2025 | First quarter of fiscal year 2025 |
| Fiscal Year End | 1231 | Indicates the company's fiscal year concludes on December 31st |
| Fiscal Years Covered | 2020-2024 | Executive compensation data spans these years. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Crinetics Pharmaceuticals, Inc. (CRNX)?
Crinetics Pharmaceuticals, Inc. has 50 recent SEC filings from Feb 2024 to Apr 2026, including 24 8-K, 10 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CRNX filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 47 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Crinetics Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Crinetics Pharmaceuticals, Inc. (CRNX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Crinetics Pharmaceuticals, Inc.?
Key financial highlights from Crinetics Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CRNX?
The investment thesis for CRNX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Crinetics Pharmaceuticals, Inc.?
Key executives identified across Crinetics Pharmaceuticals, Inc.'s filings include Dana Pizzuti, Matthew Fust, John F. Milligan, R. Paul Stuppy, Dr. Michael R. Levitt and 6 others.
What are the main risk factors for Crinetics Pharmaceuticals, Inc. stock?
Of CRNX's 31 assessed filings, 2 were flagged high-risk, 11 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Crinetics Pharmaceuticals, Inc.?
Forward guidance and predictions for Crinetics Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.